JP2016502974A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016502974A5 JP2016502974A5 JP2015545914A JP2015545914A JP2016502974A5 JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5 JP 2015545914 A JP2015545914 A JP 2015545914A JP 2015545914 A JP2015545914 A JP 2015545914A JP 2016502974 A5 JP2016502974 A5 JP 2016502974A5
- Authority
- JP
- Japan
- Prior art keywords
- gdc
- combination
- cancer
- acceptable salt
- mehd7945a
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000003839 salts Chemical class 0.000 claims description 30
- 239000011780 sodium chloride Substances 0.000 claims description 30
- 108010054608 MEHD7945A Proteins 0.000 claims description 28
- LHNIIDJUOCFXAP-UHFFFAOYSA-N pictrelisib Chemical compound C1CN(S(=O)(=O)C)CCN1CC1=CC2=NC(C=3C=4C=NNC=4C=CC=3)=NC(N3CCOCC3)=C2S1 LHNIIDJUOCFXAP-UHFFFAOYSA-N 0.000 claims description 28
- GRZXWCHAXNAUHY-NSISKUIASA-N (2S)-2-(4-chlorophenyl)-1-[4-[(5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl]piperazin-1-yl]-3-(propan-2-ylamino)propan-1-one Chemical compound C1([C@H](C(=O)N2CCN(CC2)C=2C=3[C@H](C)C[C@@H](O)C=3N=CN=2)CNC(C)C)=CC=C(Cl)C=C1 GRZXWCHAXNAUHY-NSISKUIASA-N 0.000 claims description 23
- 201000010099 disease Diseases 0.000 claims description 22
- 230000003463 hyperproliferative Effects 0.000 claims description 16
- 241000124008 Mammalia Species 0.000 claims description 12
- 201000011510 cancer Diseases 0.000 claims description 12
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 claims description 8
- 206010006187 Breast cancer Diseases 0.000 claims description 6
- 102000027776 ERBB3 Human genes 0.000 claims description 6
- 101700041204 ERBB3 Proteins 0.000 claims description 6
- 230000035772 mutation Effects 0.000 claims description 6
- 230000014509 gene expression Effects 0.000 claims description 5
- 230000000051 modifying Effects 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 206010028980 Neoplasm Diseases 0.000 claims description 3
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims description 2
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims description 2
- 206010009944 Colon cancer Diseases 0.000 claims description 2
- 206010014733 Endometrial cancer Diseases 0.000 claims description 2
- 206010017758 Gastric cancer Diseases 0.000 claims description 2
- 206010018338 Glioma Diseases 0.000 claims description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 2
- 206010025650 Malignant melanoma Diseases 0.000 claims description 2
- 206010027406 Mesothelioma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 102000014160 PTEN Phosphohydrolase Human genes 0.000 claims description 2
- 108010011536 PTEN Phosphohydrolase Proteins 0.000 claims description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims description 2
- 206010060862 Prostate cancer Diseases 0.000 claims description 2
- 206010038389 Renal cancer Diseases 0.000 claims description 2
- 230000003321 amplification Effects 0.000 claims description 2
- 102000017256 epidermal growth factor-activated receptor activity proteins Human genes 0.000 claims description 2
- 108040009258 epidermal growth factor-activated receptor activity proteins Proteins 0.000 claims description 2
- 201000010536 head and neck cancer Diseases 0.000 claims description 2
- 201000010982 kidney cancer Diseases 0.000 claims description 2
- 201000005202 lung cancer Diseases 0.000 claims description 2
- 201000001441 melanoma Diseases 0.000 claims description 2
- 238000003199 nucleic acid amplification method Methods 0.000 claims description 2
- 230000002018 overexpression Effects 0.000 claims description 2
- 201000002528 pancreatic cancer Diseases 0.000 claims description 2
- 201000011549 stomach cancer Diseases 0.000 claims description 2
- 230000001225 therapeutic Effects 0.000 claims description 2
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261734796P | 2012-12-07 | 2012-12-07 | |
| US61/734,796 | 2012-12-07 | ||
| US201361888892P | 2013-10-09 | 2013-10-09 | |
| US61/888,892 | 2013-10-09 | ||
| PCT/US2013/073914 WO2014089570A1 (fr) | 2012-12-07 | 2013-12-09 | Combinaisons d'un composé inhibiteur de pi3k/akt avec un composé inhibiteur de her3/egfr et leur utilisation dans le traitement d'un trouble hyperprolifératif |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016502974A JP2016502974A (ja) | 2016-02-01 |
| JP2016502974A5 true JP2016502974A5 (fr) | 2016-12-15 |
Family
ID=49885413
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015545914A Pending JP2016502974A (ja) | 2012-12-07 | 2013-12-09 | Ｐｉ３ｋ／ａｋｔ阻害剤化合物とｈｅｒ３／ｅｇｆｒ阻害剤化合物との組み合わせ及び高増殖性疾患の治療におけるその使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9566334B2 (fr) |
| EP (1) | EP2928488A1 (fr) |
| JP (1) | JP2016502974A (fr) |
| KR (1) | KR20150092760A (fr) |
| CN (1) | CN104968363A (fr) |
| BR (1) | BR112015013196A2 (fr) |
| CA (1) | CA2894153A1 (fr) |
| HK (1) | HK1211218A1 (fr) |
| MX (1) | MX2015007054A (fr) |
| RU (1) | RU2015127037A (fr) |
| WO (1) | WO2014089570A1 (fr) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105247072B (zh) * | 2013-02-25 | 2019-10-15 | 基因泰克公司 | 检测和治疗抗药性akt突变体的方法和组合物 |
| JP6875501B2 (ja) | 2016-08-10 | 2021-05-26 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| US7312243B1 (en) * | 2003-08-29 | 2007-12-25 | Jay Pravda | Materials and methods for treatment of gastrointestinal disorders |
| GB0423653D0 (en) * | 2004-10-25 | 2004-11-24 | Piramed Ltd | Pharmaceutical compounds |
| AU2007246793B2 (en) | 2006-04-26 | 2013-02-07 | F. Hoffmann-La Roche Ag | Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor |
| UA95641C2 (en) * | 2006-07-06 | 2011-08-25 | Эррей Биофарма Инк. | Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors |
| AU2008298948B2 (en) * | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| CN101909631B (zh) | 2007-10-25 | 2012-09-12 | 健泰科生物技术公司 | 制备噻吩并嘧啶化合物的方法 |
| CN104447995A (zh) * | 2009-03-20 | 2015-03-25 | 霍夫曼-拉罗奇有限公司 | 双特异性抗-her抗体 |
| DK2544680T3 (en) * | 2010-03-11 | 2015-04-27 | Merrimack Pharmaceuticals Inc | USE OF ErbB3 INHIBITORS IN TREATMENT OF TRIPLE-NEGATIVE BREAST CANCER |
| JP6147246B2 (ja) * | 2011-04-01 | 2017-06-14 | ジェネンテック， インコーポレイテッド | Ａｋｔ及びｍｅｋ阻害剤化合物の組み合わせ、及び使用方法 |
| WO2012177925A1 (fr) * | 2011-06-21 | 2012-12-27 | The Board Institute, Inc. | Inhibiteurs akt pour le traitement d'un cancer exprimant un gène de fusion magi3 - akt3 |
| EP2780469A1 (fr) * | 2011-11-18 | 2014-09-24 | Vanderbilt University | Marqueurs de cancer du sein triple négatif et utilisations de ceux-ci |
| JP2015505959A (ja) * | 2011-12-05 | 2015-02-26 | ネステク ソシエテ アノニム | 癌を有する患者に治療を選択する方法 |
-
2013
- 2013-12-09 CA CA2894153A patent/CA2894153A1/fr not_active Abandoned
- 2013-12-09 EP EP13814710.3A patent/EP2928488A1/fr not_active Withdrawn
- 2013-12-09 KR KR1020157018031A patent/KR20150092760A/ko not_active Application Discontinuation
- 2013-12-09 RU RU2015127037A patent/RU2015127037A/ru not_active Application Discontinuation
- 2013-12-09 WO PCT/US2013/073914 patent/WO2014089570A1/fr active Application Filing
- 2013-12-09 JP JP2015545914A patent/JP2016502974A/ja active Pending
- 2013-12-09 CN CN201380072029.4A patent/CN104968363A/zh active Pending
- 2013-12-09 MX MX2015007054A patent/MX2015007054A/es unknown
- 2013-12-09 US US14/649,889 patent/US9566334B2/en not_active Expired - Fee Related
- 2013-12-09 BR BR112015013196A patent/BR112015013196A2/pt not_active Application Discontinuation
-
2015
- 2015-12-08 HK HK15112070.1A patent/HK1211218A1/xx unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014509659A5 (fr) | ||
| JP2014512354A5 (fr) | ||
| JP2014512356A5 (fr) | ||
| RU2013148728A (ru) | Комбинации соединений, ингибирующих акт, и эрлотиниба и способы их применения | |
| JP2014512355A5 (fr) | ||
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| RU2018102078A (ru) | Комбинированная терапия противоопухолевым алкалоидом | |
| JP2014509657A5 (fr) | ||
| RU2016141570A (ru) | Комбинации ингибитора fgfr и ингибитора igf1r | |
| RU2012156903A (ru) | Способы комбинированной терапии для лечения пролиферативных заболеваний | |
| NZ598137A (en) | Oxazine derivatives and their use in the treatment of neurological disorders | |
| JP2015512398A5 (fr) | ||
| GB201205669D0 (en) | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof | |
| MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
| GEP201706786B (en) | Methods and drug products for treating alzheimer's disease | |
| MY178919A (en) | Antibody drug conjugates (adc) that bind to flt3 proteins | |
| Kleibeuker et al. | Combining radiotherapy with sunitinib: lessons (to be) learned | |
| MX2014013039A (es) | Uso de laquinimod de dosis alta para el tratamiento de esclerosis multiple. | |
| WO2016051398A8 (fr) | Immunothérapie spécifique du patient pour le traitement de tumeurs hétérogènes | |
| MX2021002321A (es) | Nuevos metodos. | |
| MX2019004514A (es) | Conjugados de anticuerpo farmaco (adc) que enlazan a las proteinas 158p1d7. | |
| EA201891931A1 (ru) | Новые ингибиторы фосфатидилинозитол-3-киназы гамма | |
| RU2014144254A (ru) | Комбинированные продукты, содержащие ингибиторы тирозинкиназ, и их применение | |
| RU2018138626A (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| MX369518B (es) | Combinacion de inhibidor de p13k e inhibidor de c-met. |